Comparing the efficacy of three bioceramic matrices for the release of vancomycin hydrochloride

A number of calcium phosphate materials have been investigated as drug release matrices for the prophylactic treatment of implant‐related osteomyelitis. However, some studies have shown the influence of processing on the efficacy of the delivered drug. The objective of this study was to evaluate the...

Full description

Saved in:
Bibliographic Details
Published inJournal of biomedical materials research. Part B, Applied biomaterials Vol. 93B; no. 1; pp. 51 - 58
Main Authors Jiang, Peih-Jeng, Patel, Sarika, Gbureck, Uwe, Caley, Ryan, Grover, Liam M.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.04.2010
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A number of calcium phosphate materials have been investigated as drug release matrices for the prophylactic treatment of implant‐related osteomyelitis. However, some studies have shown the influence of processing on the efficacy of the delivered drug. The objective of this study was to evaluate the influence of pH during processing on the efficacy of vancomycin hydrochloride (VH) against Staphylococcus aureus. VH was loaded into a brushite cement (CaHPO4·2H2O; pH 2.4); a hydroxyapatite cement (Ca10(PO4)6OH2; pH 9.4); and an apatite xerogel (pH 7.4). The pH of the material during processing had a significant influence on the mechanism of release from the cement. VH released from the apatite cement (pH 9.4) was not released in accordance with the Higuchi model. In addition to affecting release, the basic pH was shown to diminish the antibacterial potency of the released VH. Despite exceeding the minimum inhibitory concentration, the eluent from the apatite cement was ineffective against a culture of S. aureus. The findings of this study reinforce the importance of evaluating not only the release of the drug from the material matrix but also the antibacterial potency of the released drug. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2010
Bibliography:ArticleID:JBM31557
istex:213CD4C16D66DA05F59A08A223E48A2C32353156
ark:/67375/WNG-41K3TKV3-V
Advantage West Midlands (AWM)
European Regional Development Fund (ERDF)
These authors contribued equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1552-4973
1552-4981
1552-4981
DOI:10.1002/jbm.b.31557